Transcriptome analysis in osteoarthritis primary tissues identifies high-confidence effector genes

Georgia Katsoula1,2, Ana Luiza Arruda2,3, Mauro Tutino2

  • 1Technical University of Munich (TUM), TUM University Hospital, TUM School of Medicine and Health, Munich, Germany.

Nature Communications
|June 29, 2026
PubMed

Insights

This study maps gene regulation in osteoarthritis tissues, identifying novel genetic links and potential drug targets like LGALS3 and SMAD7 for this widespread joint disorder.

Area of Science:

  • Genomics
  • Molecular Biology
  • Rheumatology

Background:

  • Osteoarthritis is a degenerative joint disease affecting 600 million people globally.
  • Current treatments manage symptoms, lacking disease modification.
  • Understanding molecular mechanisms is key to developing new therapies.

Purpose of the Study:

  • To create a comprehensive map of gene regulation in osteoarthritis-relevant tissues.
  • To identify genetic variants influencing osteoarthritis risk and gene expression.
  • To discover potential therapeutic targets for osteoarthritis.

Main Methods:

  • Generated expression quantitative trait loci (eQTL) maps from knee cartilage, synovium, and fat pad tissues.
  • Integrated eQTL data with the largest osteoarthritis genome-wide association study (GWAS).
  • Utilized functional genomics to delineate regulatory architectures of risk variants.

Main Results:

  • Identified 10,166 unique eQTL-associated genes, with 61.1% being novel in osteoarthritis.
  • Discovered cartilage grade-specific genetic regulation.
  • Prioritized 45 high-confidence effector genes, revealing altered expression of chondrogenic and hypertrophic signaling pathways.

Conclusions:

  • Osteoarthritis genetic risk is linked to dysregulated chondrogenic and hypertrophic pathways.
  • Drug repurposing opportunities exist for LGALS3 and SMAD7 in osteoarthritis treatment.
  • This research provides a foundation for precision medicine approaches in osteoarthritis.

Related Concept Videos